Continuous Glucose Monitoring Can Predict Microvascular Complications in Type 1 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 22, 2025 -- Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin, according to a study published online Jan. 8 in Diabetes Technology & Therapeutics.
Boris P. Kovatchev, Ph.D., from the University of Virginia in Charlottesville, and colleagues examined the association of CGM metrics with microvascular complications of type 1 diabetes observed during the DCCT and established time-in-range (TIR) as a marker for glycemic control. Virtual CGM traces were added to the original DCCT data for each participant using a multistep machine-learning procedure.
The researchers found that TIR (70 to 180 mg/dL) computed from virtual CGM data for 14 days prior to each glycated hemoglobin measure reflected the observed differences in glycemic control between the intensive and conventional DCCT groups, with TIR >60 percent and <40 percent in these groups, respectively. TIR was associated with the risk for development or progression of retinopathy, nephropathy, and neuropathy, similar to glycated hemoglobin. TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data.
"We have demonstrated a strong association of TIR with the risk of development or progression of retinopathy and with the development of microalbuminuria," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes
TUESDAY, April 8, 2025 -- For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according...
mHealth-Supported Intervention Boosts Physical Activity in Adults With Newly Diagnosed Diabetes
TUESDAY, April 8, 2025 -- A mobile health (mHealth)-supported home-delivered physical activity (PA) intervention is feasible and effective at promoting sustained, purposeful...
Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to 2023
FRIDAY, April 4, 2025 -- From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with type 1 diabetes, and glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.